Vaxcell Bio Therapeutics
KOSDAQ:323990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vaxcell Bio Therapeutics
Retained Earnings
Vaxcell Bio Therapeutics
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vaxcell Bio Therapeutics
KOSDAQ:323990
|
Retained Earnings
-₩54.4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Retained Earnings
₩4.4T
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Retained Earnings
₩445.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Retained Earnings
-₩189.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Retained Earnings
₩218.5B
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
45%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Retained Earnings
-₩436.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Vaxcell Bio Therapeutics
Glance View
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.
See Also
What is Vaxcell Bio Therapeutics's Retained Earnings?
Retained Earnings
-54.4B
KRW
Based on the financial report for Dec 31, 2024, Vaxcell Bio Therapeutics's Retained Earnings amounts to -54.4B KRW.
What is Vaxcell Bio Therapeutics's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-26%
Over the last year, the Retained Earnings growth was -25%. The average annual Retained Earnings growth rates for Vaxcell Bio Therapeutics have been -27% over the past three years , -26% over the past five years .
